CureVac BV (NASDAQ:CVAC) shares have been volatile over the past week, gaining some 25% to $4.23, amid increased trading volume following the U.S.’s first human death from H5N1 bird flu.
What To Know: While the CDC maintains that the public risk remains low, the outbreak has already devastated poultry farms across 16 states. The news has driven interest in vaccine developers, including CureVac, which is collaborating with GSK plc (NYSE:GSK) to test updated mRNA-based bird flu vaccine candidates.
With $72 million recently allocated by the U.S. government for bird flu vaccine production and competitors like Moderna securing substantial funding, investors speculate that CureVac could gain from similar opportunities. The company's mRNA technology could provide a next-generation solution, though its current vaccines target earlier strains.
CureVac's relatively smaller market cap could also make it more sensitive to speculative activity, and any developments in bird flu preparedness could impact its share price significantly.
Read Also: US Stocks To Open On A Tentative Note As Traders Remain Cautious Ahead Of Friday’s Crucial Jobs Data
How To Buy CVAC Stock
By now you're likely curious about how to participate in the market for CureVac – be it to purchase shares, or even attempt to bet against the company.
According to data from Benzinga Pro, CVAC has a 52-week high of $5.28 and a 52-week low of $2.22.
Image courtesy of CureVac
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
